Eminence Capital’s Exact Sciences EXAS Stock Holding History

Eminence Capital’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,469,746	Closed	-$97.3M	–	65
2022 Q2	$97.3M	Buy	2,469,746 +222,278	+10%	+$11.9M	1.93%	22
2022 Q1	$157M	Sell	2,247,468 -557	-0%	-$40.7K	1.78%	9
2021 Q4	$175M	Buy	2,248,025 +833,812	+59%	+$73.6M	1.66%	12
2021 Q3	$135M	Buy	1,414,213 +317,900	+29%	+$33.6M	1.82%	26
2021 Q2	$136M	Buy	1,096,313 +346,225	+46%	+$41.3M	1.68%	27
2021 Q1	$98.8M	Sell	750,088 -191,770	-20%	-$26.3M	1.22%	39
2020 Q4	$125M	Sell	941,858 -394,897	-30%	-$47.8M	1.17%	34
2020 Q3	$136M	Buy	1,336,755 +196,045	+17%	+$16.9M	1.34%	19
2020 Q2	$99.2M	Buy	1,140,710 +802,114	+237%	+$64.1M	0.98%	34
2020 Q1	$19.6M	Buy	+338,596	New	+$27.5M	0.21%	92

Other funds holding EXAS

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Eminence Capital's EXAS Position: Q3 2022 in Review

Eminence Capital sold out of Exact Sciences (EXAS) in Q3 2022, closing a stake of 2,469,746 shares — an estimated $97.3M sold.

Eminence Capital first reported a position in EXAS in Q1 2020 and held it in 10 quarters. The position peaked at $175M in Q4 2021. 480 funds tracked by Wall St. Rank hold EXAS as of Q3 2022.

Eminence Capital reported no remaining Exact Sciences position as of Q3 2022 after selling out during the quarter.
Eminence Capital sold 2,469,746 Exact Sciences shares in Q3 2022, an estimated $97.3M.
Eminence Capital first reported a position in Exact Sciences in Q1 2020 and held it in 10 quarters.
Eminence Capital's Exact Sciences position peaked at $175M in Q4 2021.
480 funds tracked by Wall St. Rank held Exact Sciences as of Q3 2022.

Based on Eminence Capital's 13F filing for Q3 2022, filed 14 Nov 2022.